Equillium (EQ) Payables (2017 - 2026)
Equillium (EQ) posted quarterly Payables of $1.3 million for Q1 2026, down 57.65% year-over-year from $3.1 million in Q1 2025, and up 71.52% quarter-over-quarter from $755000.0 in Q4 2025.
Analysis
Equillium (EQ) Payables (2017 - 2026) Analysis & Trends
Equillium (EQ) has reported Payables for 10 consecutive years, with $1.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Payables fell 57.65% year-over-year to $1.3 million; the TTM figure through Mar 2026 stood at $1.3 million (down 57.65% YoY), while the FY2025 annual figure was $755000.0, down 71.79% from the prior year.
- Payables advanced to $1.3 million in Q1 2026 per EQ's latest filing, from $755000.0 in the prior quarter.
- Across five years, Payables topped out at $11.4 million in Q1 2023 and bottomed at $755000.0 in Q4 2025.
- Historically, Payables has averaged $4.8 million across 5 years, with a median of $3.7 million in 2024.
- Annual changes were most pronounced in 2022 — Payables soared 416.35% — and 2024, when it sank 75.64%.
- Equillium's Payables stood at $9.7 million in 2022, then tumbled by 51.43% to $4.7 million in 2023, then plunged by 43.15% to $2.7 million in 2024, then slumped by 71.79% to $755000.0 in 2025, then jumped by 71.52% to $1.3 million in 2026.
- Business Quant data shows EQ's Payables at $1.3 million in Q1 2026, $755000.0 in Q4 2025, and $1.1 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 167.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 88.42 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 470.30 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 108.02 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 35.57 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Equillium | 249.33 Mn | 249.33 Mn | - | 850,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 850,000.00 |
| Mar 31, 2026 | 1.30 Mn |
| Dec 31, 2025 | 755,000.00 |
| Sep 30, 2025 | 1.08 Mn |
| Jun 30, 2025 | 4.81 Mn |
| Mar 31, 2025 | 3.06 Mn |
| Dec 31, 2024 | 2.68 Mn |
| Sep 30, 2024 | 3.67 Mn |
| Jun 30, 2024 | 4.49 Mn |
| Mar 31, 2024 | 2.78 Mn |
| Dec 31, 2023 | 4.71 Mn |
| Sep 30, 2023 | 3.64 Mn |
| Jun 30, 2023 | 3.03 Mn |
| Mar 31, 2023 | 11.41 Mn |
| Dec 31, 2022 | 9.69 Mn |
| Sep 30, 2022 | 8.18 Mn |
| Jun 30, 2022 | 9.38 Mn |
| Mar 31, 2022 | 7.07 Mn |
| Dec 31, 2021 | 2.65 Mn |
| Sep 30, 2021 | 3.92 Mn |